Alector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into a drug that aims to tackle Alzheimer’s by modifying the brain’s immune system.

Alector said Gary Romano is stepping down as medical chief after about three years in the role, and will be replaced by Giacomo Salvadore. The late-stage clinical biotechnology company with a ...

Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- "It has been a privilege to work alongside the talented team at Alector to advance a pipeline of therapies designed to ...

Alector (ALEC) announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of ...